| abstract |
There are presented compounds of the formula n nor pharmaceutically acceptable salts thereof,n nwherein Y 1 , Y 2 , X 1 , X 2 , X 3 and R are as described in this application. These compounds are believed to inhibit MDM2-p53 interaction and as such the compounds will have anti-hyperproliferative cellular activity. |